Repligen surges after settling patent suit with Bristol-Myers
Shares of Repligen Corp. (Nasdaq:RGEN) rocketed in pre-market trading after the biopharmaceutical company said that it settled a patent infringement lawsuit with Bristol-Myers Squibb Co. (NYSE:BMY) over Bristol-Myers’ sale of Orencia for the treatment of rheumatoid arthritis.
Shares spiked 30.9%, or $1.74, to $7.20 in pre-market trading. For detailed price information and recent news stories about Repligen, click RGEN.
